Oncology, Domestic Firms Dominate New China Approvals As Innovation Gathers Pace
China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years.
You may also be interested in...
The China bioventure sector is poised to set a record for initial public offerings and fundraising, but one therapeutic area is taking a surprise lead - immunology.
Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.
One initial public offering and six private funding deals add a total of $357m into the biotech funding pot in China as multiple new ventures look to progress pipeline assets and build capabilities.